| Bioactivity | AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premature ventricular complexes and ventricular fibrillation in experimental arrhythmia models. AH-1058 effectively inhibits both ventricular tachycardia and ventricular fibrillation in the reperfusion-induced arrhythmia model in rats. AH-1058 demonstrates potent calcium channel-blocking effects, suppressing L-type Ca2+ currents in isolated cardiomyocytes. |
| CAS | 228123-15-7 |
| Formula | C30H29ClN2O3 |
| Molar Mass | 501.02 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Effects of AH-1058, a new antiarrhythmic drug, on experimental arrhythmias and cardiac membrane currents |
AH-1058
CAS: 228123-15-7 F: C30H29ClN2O3 W: 501.02
AH-1058 is a newly synthesized antiarrhythmic agent that exhibits significant antiarrhythmic activity by delaying premat
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.